Rare Pediatric Disease Voucher Program Gains Temporary Extension From House Committee

US incentive program would gain only four more years, despite calls for a permanent extension.

Capitol House
Pallone did not favor a permanent extension of the rare pediatric priority review voucher program in part because of the strain it puts on the FDA. • Source: Shutterstock

The rare pediatric disease priority review voucher would be saved under pending House legislation, but advocates would have to fight to keep it alive again in 2024.

House Energy and Commerce Committee members on 9 September sent to the full chamber a bill that would continue the voucher program, but only until 30 September 2024. The original legislation offered by Rep. G.K. Butterfield, D-NC, known as the Creating Hope Reauthorization Act, would have made the program permanent. Committee Chairman Frank Pallone, D-NJ, offered the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Pink Sheet

US FDA Restoring Some Library Resources

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

Recent and Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.